Trevena, Inc. Receives Research Funding for Parkinson’s Disease from The Michael J. Fox Foundation
Published: Dec 19, 2011
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that The Michael J. Fox Foundation (MJFF) has awarded the company a $205,000 research funding grant for Parkinson’s disease research. The one-year Target Validation Funding Award will support pathway validation experiments to demonstrate the potential of novel biased ligands to the delta-opioid receptor as potential treatments for Parkinson’s disease.